Das Portal der Prozessanalytik PAT - Technologie und Prozesskontrolle

 

 




Fachberichte - Systemkomponeten - Probenaufbereitung - Entnahmesonden - Kühler - PAT- Pressen - Probenaufbereitungen - Sensoren - Ventile

Fachberichte

Tagungen

Prozessanalytik - generell

Gasanalytik

Flüssigkeitsanalytik

Feststoffanalytik

Partikelanalytik

Physikalische Parameter

Automatisierungslösungen Kontrolltechnologie

Systemkomponenten Probenaufbereitung

Dienstleister

 


Rubriken : Systemkomponenten / Probenaufbereitung - Dienstleister
Provider of quality life science research reagents and services




  AMSBIO Launch New Screening Company

- OncoScreen service - the first application platform launched by ScreenIn3D is targeted at improving anticancer drug treatment -

12. July 2018

ScreenIn3D (Glasgow, UK)
is a new joint venture company set up by AMSBIO and the University of Strathclyde exploiting the latest advances in microfluidics and 3D culture to develop a novel microfluidic screening platform.

The unique combination

of microfluidic lab-on-a-chip technology with physiologically relevant 3D spheroids is designed to make drug discovery more closely relevant with what happens in the body. The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies do 100x more testing for the same money spent as well as increasing productivity as it enables more experiments to be done on the same platform at the same time.

OncoScreen service
- the first application platform launched by ScreenIn3D is targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions using patient derived tissue. 
Chosen by the Society for Laboration Automation & Screening (SLAS Europe) as an exciting innovation technology company (presented at SLAS Europe 2018), the ONCOSCREEN service offers users the ability to reduce and replace animal models in cancer research. As well as offering 100-fold greater throughput than existing cancer screening assays for same cost – ONCOSCREEN also provides a larger screening capability of patient derived tissue than any existing services.

Alex Sim, Managing Director of AMSBIO and ScreenIn3D
said “The OncoScreen platform presents exciting possibilities for testing patient-derived multicellular tumor spheroids/organoids (comprising cancer cells, stromal cells, cancer stem cells and/or immune cells) for disease/biomarker-oriented drug activity and profiling using single- and pair-wise standard/targeted drug combinations”. He added “we are actively seeking partners and investors to fast track development of further platforms. Additional R&D grants to enhance our immunotherapy and neuroscience programs are being applied for with our collaborators. 

For further information
please visit www.screenin3d.com or contact AMSBIO on 44-1235-828200/ +1-617-945-5033 / info@amsbio.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO can draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as an expert in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance organoid and spheroid type screening outcomes from a technological and cost-effective perspective.

---------------------

Worldwide HQ 


AMS Biotechnology (AMSBIO)

184 Milton Park
Abingdon
Oxon OX14 4SE
UK

 

 


top

©

Analytic Journal Kontakt Der Analytik-Brief - Abo Firmen-Eintrag Das Analytic Journal Impressum Sitemap